Related Experiment Video
Updated: Jun 13, 2026
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
PAR-4 as a possible new target for pancreatic cancer therapy
Asfar S Azmi1, Philip A Philip, Syed F Zafar
1Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA. azmia@karmanos.org
Importance Of The Field:
Pancreatic cancer (PC) is a deadly disease that is intractable to currently available treatment regimens. Although well described in different tumors types, the importance of apoptosis inducer prostate apoptosis response-4 (Par-4) in PC has not been appreciated. PC is an oncogenic kras driven disease, which is known to downregulate Par-4. Therefore, this review highlights its significance and builds a strong case supporting the role of Par-4 as a possible therapeutic target in PC.
Areas Covered In This Review:
Literature-based evidence spanning the last 15 years on Par-4 and its significance in PC.
What The Reader Will Gain:
This review provides comprehensive knowledge of the significance of Par-4 and its association with kras status in PC, along with the crosstalk with crucial resistance and survival molecules NF-kappaB and Bcl-2 that ultimately are responsible for the overall poor outcome of different therapeutic approaches in this disease.
Take Home Message:
Par-4 holds promise as a potential therapeutic target that can be induced by chemopreventive agents and small-molecule inhibitors either alone or in combination with standard chemotherapeutics leading to selective apoptosis in PC cells. It also acts as a chemosensitizer and therefore warrants further clinical investigations in this disease.
Insights
Prostate apoptosis response-4 (Par-4) is a promising therapeutic target for pancreatic cancer (PC). Inducing Par-4 can selectively trigger apoptosis in PC cells and enhance treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Pancreatic cancer (PC) remains a lethal disease with limited treatment options.
- The role of the apoptosis inducer prostate apoptosis response-4 (Par-4) in PC is underappreciated.
- PC is driven by oncogenic Kras, which typically downregulates Par-4.
Purpose of the Study:
- To review the significance of Par-4 in pancreatic cancer.
- To establish Par-4 as a potential therapeutic target for PC.
- To explore the association between Par-4, Kras status, and therapeutic resistance.
Main Methods:
- Literature review of Par-4 and PC over the past 15 years.
- Analysis of Par-4's interaction with key survival and resistance molecules.
- Evaluation of Par-4's role in Kras-driven pancreatic cancer.
Main Results:
- Comprehensive understanding of Par-4's significance in PC.
- Detailed insights into Par-4's association with Kras status.
- Explanation of Par-4's crosstalk with NF-kappaB and Bcl-2, contributing to therapeutic resistance.
Conclusions:
- Par-4 shows promise as a therapeutic target for PC.
- Par-4 can be induced by chemopreventive agents and small-molecule inhibitors.
- Par-4 acts as a chemosensitizer, warranting further clinical investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...